SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on August 3, 2018. The report addresses a material definitive agreement entered into on the same date. Note: The request metadata referenced "AIM Immunotech Inc.," but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment and does not contain financial statements or performance metrics.
Material Changes
The registrant amended its Equity Distribution Agreement with Maxim Group LLC, originally dated July 23, 2012. The sole purpose of this amendment was to add a new registration statement on Form 3 (File No. 333-226059) to the definition of "registration statement" because the previous registration statement had expired.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the administrative update to the distribution agreement.
Key Facts for Investor Verification
- Verify the status and terms of the new Form 3 registration statement (File No. 333-226059) referenced in the amendment.
- Confirm the current terms of the Equity Distribution Agreement with Maxim Group LLC via Exhibit 10.1.
- Review recent financial filings (e.g., 10-K or 10-Q) for actual financial performance data, as this 8-K does not include such metrics.